| Pair Name | Celastrol, Histone deacetylase inhibitor | ||
| Phytochemical Name | Celastrol (PubChem CID: 122724 ) | ||
| Anticancer drug Name | Histone deacetylase inhibitor (PubChem CID: 10095659 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Celastrol, Histone deacetylase inhibitor | |||
| Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
| Gene Regulation | Up-regulation | Acetylation | H4K16 | KEGG ID N.A. |
| In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
| NCI-H1299 | Lung large cell carcinoma | Homo sapiens (Human) | CVCL_0060 | |
| LL/2 (LLC1) | Malignant tumors of the mouse pulmonary system | Mus musculus (Mouse) | CVCL_4358 | |
| HeLa | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_0030 | |
| Result | Celastrol treatment significantly enhanced the suppressive effects of HDACi on lung cancer cell allografts in mice, with significant H4K16ac upregulation, indicating that a combination of celastrol and HDACi is a potential novel therapeutic approach for patients with lung cancer. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Celastrol inhibits lung cancer growth by triggering histone acetylation and acting synergically with HDAC inhibitors. Pharmacol Res. 2022 Nov;185:106487. doi: 10.1016/j.phrs.2022.106487. | Click |
